Rama Sundari Akondy

Rama Sundari Akondy

Auto-generated profile, based on publicly available information

Rama Sundari Akondy

Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2008 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
TQTroy D Querec
Troy D Querec
RARama S Akondy
Rama S Akondy
ELEva K Lee
Eva K Lee
WCWeiping Cao
Weiping Cao
Helder NakayaHelder Nakaya
Helder Nakaya
BPBali Pulendran
Bali Pulendran

26 April 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AKAlice O. Kamphorst
Alice O. Kamphorst
RPRathi N. Pillai
Rathi N. Pillai
SYShu Yang
Shu Yang
TNTahseen H. Nasti
Tahseen H. Nasti
RARama S. Akondy
Rama S. Akondy
SRSuresh S. Ramalingam
Suresh S. Ramalingam
Exhausted T cells in chronic infections and cancer have sustained expression of the inhibitory receptor programmed cell death 1 (PD-1). Therapies that block the PD-1 pathway have shown promising clinical results in a significant number of advanced-stage cancer patients. Nonetheless, a better understanding of the immunological responses induced by PD-1 blockade in cancer patients is lacking. Identification of predictive biomarkers is a priority in the field, but whether peripheral blood analysis can provide biomarkers to monitor or predict patients’ responses to treatment remains to be resolved. In this study, we analyzed longitudinal blood samples from advanced stage non–small cell lung cancer (NSCLC) patients (n = 29) receiving PD-1–targeted therapies. We detected an increase in Ki-67+ PD-1+ CD8 T cells following therapy in ∼70% of patients, and most responses were induced after the first or second treatment cycle. This T-cell activation was not indiscriminate because we observed only minimal effects on EBV-specific CD8 T cells, suggesting that responding cells may be tumor specific. These proliferating CD8 T cells had an effector-like phenotype (HLA-DR+, CD38+, Bcl-2lo), expressed costimulatory molecules (CD28, CD27, ICOS), and had high levels of PD-1 and coexpression of CTLA-4. We found that 70% of patients with disease progression had either a delayed or absent PD-1+ CD8 T-cell response, whereas 80% of patients with clinical benefit exhibited PD-1+ CD8 T-cell responses within 4 wk of treatment initiation. Our results suggest that peripheral blood analysis may provide valuable insights into NSCLC patients’ responses to PD-1–targeted therapies.

15 February 2010 in Journal of Experimental Medicine
Verified
Journal Article
Open access
DMDavid Masopust
David Masopust
DCDaniel Choo
Daniel Choo
VVVaiva Vezys
Vaiva Vezys
EWE. John Wherry
E. John Wherry
JDJaikumar Duraiswamy
Jaikumar Duraiswamy
RARafi Ahmed
Rafi Ahmed
Migration to intestinal mucosa putatively depends on local activation because gastrointestinal lymphoid tissue induces expression of intestinal homing molecules, whereas skin-draining lymph nodes do not. This paradigm is difficult to reconcile with reports of intestinal T cell responses after alternative routes of immunization. We reconcile this discrepancy by demonstrating that activation within spleen results in intermediate induction of homing potential to the intestinal mucosa. We further demonstrate that memory T cells within small intestine epithelium do not routinely recirculate with memory T cells in other tissues, and we provide evidence that homing is similarly dynamic in humans after subcutaneous live yellow fever vaccine immunization. These data explain why systemic immunization routes induce local cell-mediated immunity within the intestine and indicate that this tissue must be seeded with memory T cell precursors shortly after activation.

1 November 2008 in The Lancet
Verified
Journal Article
Closed access
MMM Juliana McElrath
M Juliana McElrath
SRStephen C De Rosa
Stephen C De Rosa
ZMZoe Moodie
Zoe Moodie
SDSheri Dubey
Sheri Dubey
LKLisa Kierstead
Lisa Kierstead
DCDanilo R Casimiro
Danilo R Casimiro

1 May 2008 in Immunity
Verified
Journal Article
Closed access
JMJoseph D. Miller
Joseph D. Miller
RMRobbert G. van der Most
Robbert G. van der Most
RARama S. Akondy
Rama S. Akondy
JGJohn T. Glidewell
John T. Glidewell
SASophia Albott
Sophia Albott
RARafi Ahmed
Rafi Ahmed

1 December 2008 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
DGDenis Gaucher
Denis Gaucher
RTRene Therrien
Rene Therrien
NKNadia Kettaf
Nadia Kettaf
BABastian R. Angermann
Bastian R. Angermann
GBGeneviève Boucher
Geneviève Boucher
RSRafick-Pierre Sékaly
Rafick-Pierre Sékaly
Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.